IVIG is a therapeutic preparation that contains a variety of immunoglobulins, including IgG antibodies, because it is manufactured by pooling plasma from thousands of donors. and the blood group was A?+?in five and B?+?in two. None of the individuals received immunomodulatory therapy or reddish blood cell transfusions. They were adopted for any yr and all recovered. Conclusion Especially, in non-O blood group KD individuals who are refractory to initial IVIG and require a second dose of IVIG or 10% formulation the possibility of immune hemolytic anemia should be cautiously regarded as, and close follow-up should be managed after therapy. Keywords: Kawasaki disease, Intravenous immunoglobulin, Hemolytic anemia Background Since the development of highly-purified intravenous immunoglobulin (IVIG) preparations in the 1980s, a new unmodified preparation known as native IVIG has been developed. This is now the standard of care in alternative therapy for individuals with main immunodeficiency and has been widely used as a treatment modality for numerous clinical conditions, providing immunomodulatory and anti-inflammatory effects [1]. IVIG therapy is the standard treatment for Kawasaki disease (KD) to reduce the risk of coronary complications [2]. IVIGs effectiveness be related to its neutralizing antibody activity against inflammatory cytokines and bacterial enterotoxins; [3] infused antibodies will also be thought to prevent immune-mediated damage obstructing cytotoxic T-lymphocyte acknowledgement of infected cells. IVIG offers been shown to reduce endothelial cell death by neutralizing the effects of cytokines, obstructing the response of endothelial cells to cytokines, or obstructing the production of cytokines and growth factors [4, 5]. IVIG is generally safe and well tolerated, but it may be associated with particular side effects. Common side effects of IVIG may include slight to moderate reactions in the infusion site, such as pain, swelling, or redness. Potentially serious side effects of IVIG include allergic or hypersensitivity reactions [6]. These reactions can range from slight allergic symptoms such as rash Fam162a or itching to more severe reactions such as difficulty breathing, tightness in the chest, or anaphylaxis, a severe and life-threatening allergic reaction [7]. It is important to note that severe allergic reactions are rare but can Ebrotidine occur, especially Ebrotidine in individuals with a history of allergic reactions to IVIG or additional blood products. In addition, Ebrotidine IVIG may hardly ever become associated with particular systemic adverse effects, such as blood clotting disorders, kidney problems, or aseptic meningitis [8]. These adverse reactions are relatively rare, but should be monitored. IVIG-induced hemolysis is definitely a rare but known complication. However, the mechanism is not fully recognized. Earlier studies have shown that approximately 2.5% of KD patients receiving IVIG may develop IVIG-associated hemolytic anemia [9]. Case demonstration The authors statement seven instances of immune hemolytic anemia in Kawasaki disease and review the literature. In our center, we have performed a follow-up blood test 36 to 48?h after the completion of IVIG treatment in individuals with KD. Earlier, we analyzed the laboratories of KD children in our center and found that the switch in hemoglobin level was within 1.5?g/dL in the blood test performed 48?h after IVIG infusion. Consequently, we have been looking at for hemolysis if the hemoglobin experienced decreased by 1.5?g/dL compared to pretreatment, they were evaluated for hemolysis. During six years, 367 individuals were treated with the same product, IVIG. At our institution, a total of 588 individuals were diagnosed with Kawasaki disease during the Ebrotidine period, of which 367 individuals received the 10% formulation and seven individuals experienced hemolytic anemia. Prior to this period, the 10% formulation was not in use. During this period, the decision to use the 10% or 5% formulation for an individual patient is at the discretion of the physician. Of the 376 individuals who received the 10% formulation, seven individuals developed hemolytic anemia, of which 5 were type A, 2 were type B, and none were type O. None of the 226 individuals who received the 5% formulation developed hemolytic.